Table 1.
Effects of CoQ10 and CoQH2 on cardiovascular diseases. Empty cells are used if information is missing
| Author | Year | Probands included | Duration supplementation/(study) [weeks] | Daily intake (mg/d) | Effect | Reduced cardiovascular mortality (%) | |
|---|---|---|---|---|---|---|---|
| CoQ10 | Judy et al. [16] | 1993 | 20 | 6/(6) | 100 | Improved echocardiogram and improved EF | |
| Morisco et al. [17] | 1993 | 641 | 52/(52) | 160 | Reduced time of hospitalisation | ||
| Chello et al. [18] | 1994 | 40 | 1/(1) | 150 | No reduced cardiovascular mortality | 0 | |
| Morisco et al. [19] | 1994 | 6 | 4/(8) | 200 | Improved echocardiogram Improved EF | ||
| Singh et al. [20] | 1998 | 144 | 4/(4) | 120 | Reduced cardiovascular mortality | 15.90 | |
| Berman et al. [21] | 2004 | 32 | 12/(12) | 60 | Improved clinical status, improved 6-min walk test and improved NYHA class | ||
| Chew et al. [22] | 2008 | 74 | 24/(24) | 160 | No improved E/e´ ratio | ||
| Makhija et al. [23] | 2008 | 30 | 7/(7) | 165 | Reduced time of hospitalisation | ||
| Kuimov et al. [24] | 2013 | 8/(8) | 60 | Improved clinical status | |||
| Mortensen et al. [25••] | 2014 | 420 | 16/(104) | 300 | Improved NYHA class, reduced time of hospitalisation and reduced cardiovascular mortality | 18.00 | |
| Aslanabadi et al. [26] | 2016 | 100 | 0.14/(0.14) | 300 | Reduced cardiovascular mortality | 2.00 | |
| Mortensen et al. [27] | 2019 | 231 | 12/(96) | 300 | Improved NYHA class, improved EF, reduced time of hospitalisation and reduced cardiovascular mortality | 11.00 | |
| Sobirin et al. [28] | 2019 | 28 | 4/(4) | 300 | Improved E/e´ ratio | ||
| Khan et al. [29] | 2020 | 123 | 0.14/(0.14) | 400 | Reduced BNPs and reduced time of hospitalisation | ||
| CoQ10 & Selenium | Kuklinski et al. [30] | 1994 | 61 | 52/(52) | 100 | Reduced cardiovascular mortality | 20.00 |
| Alehagen et al. [31••] | 2013 | 443 | 260/(520) | 200 | Improved echocardiogram, improved EF, reduced BNPs and reduced cardiovascular mortality | 6.70 | |
| Alehagen et al. [32] | 2015 | 443 | 260/(520) | 200 | Reduced cardiovascular mortality | 17.90 | |
| Alehagen et al. [33] | 2015 | 443 | 148/(270) | 200 | Reduced cardiovascular mortality | 3.50 | |
| Alehagen et al. [34] | 2016 | 668 | 208/(478.4) | 200 | Reduced cardiovascular mortality | 8.00 | |
| Alehagen et al. [35] | 2018 | 434 | 208/(832) | 200 | Reduced cardiovascular mortality | 10.60 | |
| Alehagen et al. [36] | 2021 | 213 | 208/(254) | 200 | Reduced cardiovascular mortality | 10.00 | |
| Opstad et al. [37] | 2022 | 118 | 42/(520) | 200 | Reduced cardiovascular mortality | 6.00 | |
| Alehagen et al. [38] | 2022 | 443 | 148/(148) | 200 | Improved echocardiogram, improved EF, reduced BNPs and reduced cardiovascular mortality | 6.70 | |
| CoQH2 | Orlando et al. [39] | 2020 | 50 | 2/(26) | 400 | Improved echocardiogram, improved EF, no reduced cardiovascular mortality | 0 |
| Kawashima et al. [40] | 2020 | 14 | 12/(12) | 400 | No improved echocardiogram and improved endothelial function | ||
| Holmberg et al. [41] | 2021 | 43 | 1/(1) | 600 | Improved EF and no reduced cardiovascular mortality | 0 | |
| Samuel et al. [42] | 2022 | 39 | 12/(12) | 300 | No Improved E/e´ratio and no reduced BNPs | ||
| CoQH2 & Ribose | Pierce et al. [43•] | 2022 | 216 | 12/(12) | 600 | Improved clinical status, improved EF, reduced BNPs and no reduced cardiovascular mortality | 0 |